Next Article in Journal
Mycotoxin Contamination Concerns of Herbs and Medicinal Plants
Next Article in Special Issue
Klotho/FGF23 and Wnt Signaling as Important Players in the Comorbidities Associated with Chronic Kidney Disease
Previous Article in Journal
Deoxynivalenol Induces Inflammation in IPEC-J2 Cells by Activating P38 Mapk And Erk1/2
Previous Article in Special Issue
Cardiac Remodeling in Chronic Kidney Disease
Open AccessReview

Cardiovascular Calcification in Chronic Kidney Disease—Therapeutic Opportunities

Department of Internal Medicine I, Cardiology, Medical Faculty, RWTH, Aachen University, 52074 Aachen, Germany
*
Author to whom correspondence should be addressed.
A.H. and C.C. contributed equally.
Toxins 2020, 12(3), 181; https://doi.org/10.3390/toxins12030181
Received: 25 February 2020 / Revised: 11 March 2020 / Accepted: 12 March 2020 / Published: 14 March 2020
(This article belongs to the Special Issue Comorbidities in Chronic Kidney Disease (CKD))
Patients with chronic kidney disease (CKD) are highly susceptible to cardiovascular (CV) complications, thus suffering from clinical manifestations such as heart failure and stroke. CV calcification greatly contributes to the increased CV risk in CKD patients. However, no clinically viable therapies towards treatment and prevention of CV calcification or early biomarkers have been approved to date, which is largely attributed to the asymptomatic progression of calcification and the dearth of high-resolution imaging techniques to detect early calcification prior to the ‘point of no return’. Clearly, new intervention and management strategies are essential to reduce CV risk factors in CKD patients. In experimental rodent models, novel promising therapeutic interventions demonstrate decreased CKD-induced calcification and prevent CV complications. Potential diagnostic markers such as the serum T50 assay, which demonstrates an association of serum calcification propensity with all-cause mortality and CV death in CKD patients, have been developed. This review provides an overview of the latest observations and evaluates the potential of these new interventions in relation to CV calcification in CKD patients. To this end, potential therapeutics have been analyzed, and their properties compared via experimental rodent models, human clinical trials, and meta-analyses. View Full-Text
Keywords: chronic kidney disease; cardiovascular disease; vascular calcification; experimental rodent models chronic kidney disease; cardiovascular disease; vascular calcification; experimental rodent models
Show Figures

Figure 1

MDPI and ACS Style

Himmelsbach, A.; Ciliox, C.; Goettsch, C. Cardiovascular Calcification in Chronic Kidney Disease—Therapeutic Opportunities. Toxins 2020, 12, 181.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop